China NMPA Inspection - Fangqi Cosmetics Factory, Baiyun District, Guangzhou - June 18, 2021

The National Medical Products Administration (NMPA) conducted an unannounced inspection of Guangzhou Baiyun District Fangqi Cosmetics Factory, with the findings formally announced on June 18, 2021. This inspection, which occurred recently before the June 16, 2021 directive, uncovered significant non-compliance. The cosmetics manufacturer was found to be in violation of critical regulatory statutes, including the "Cosmetics Supervision and Management Regulations" and the "Cosmetics Production Licensing Work Specifications." These regulations are fundamental to ensuring the quality, safety, and proper manufacturing practices within China's cosmetics industry. The company, Guangzhou Baiyun District Fangqi Cosmetics Factory, has acknowledged the deficiencies identified during the inspection. To address these serious breaches and prioritize public health and safety in cosmetics use, the NMPA has taken decisive action. On June 16, 2021, it formally instructed the Guangdong Provincial Drug Administration to initiate a thorough investigation into the factory's operations. This directive signifies the NMPA's commitment to upholding stringent regulatory standards and taking necessary measures to ensure that cosmetic products available to the public meet established safety and quality benchmarks, thereby protecting consumer interests against substandard manufacturing practices.